Jamie Stiff

Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto.

Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada.

EBT Medical, Inc. develops disruptive neurostimulation therapies for pelvic health disorders. The firm’s services include pelvic floor disorders and overactive bladder. The company was founded by Paul Yoo and Sasha John in 2014 and is headquartered in Toronto, Canada.

BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada.

Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021.

Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD.

Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.

Therapeutic Monitoring Systems, Inc. develops clinical decision support software for use in critical care medicine. Its CIMVA software platform will be used by physicians and nurses in the hospital ICU and emergency department to improve how care is delivered, benefiting both patients and hospitals. The firm’s software is architected to facilitate point-of-care use by caregivers on browser-enabled central viewing stations or mobile devices. The company was founded by Andrew J. E. Seely in 2007 and is headquartered in Ottawa, Canada.